(2R,6R)-HNK Reverses PTSD-like Behaviors in Female Rats

Preclinical Evidence: (2R,6R)-HNK Reverses PTSD-like Traits in Female Rats

Recent research published on October 7, 2026 (OpenAlex W7220859590) demonstrates that a single dose of (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] can reverse chronic post-traumatic stress disorder (PTSD)-like behavioral traits in female rats following repetitive low-level blast injury. This finding extends previous work in male rats, offering new insights into sex-specific responses to trauma and potential treatments. The study used a validated rat model simulating blast exposures common in military contexts, with behavioral and molecular changes assessed up to 29 weeks post-injury.

Mechanistic Insights: Glutamate and Serotonin Pathways Implicated

(2R,6R)-HNK, a metabolite of the anesthetic ketamine, appears to exert its therapeutic effects by modulating glutamatergic signaling. Specifically, blast-injured female rats showed elevated levels of the metabotropic glutamate receptor mGluR2, which were normalized after (2R,6R)-HNK administration. The serotonin 5-HT2A receptor (5-HT2AR) was also decreased in injured animals, though (2R,6R)-HNK did not restore this receptor's levels. These molecular findings are consistent with the observed behavioral improvements, suggesting that (2R,6R)-HNK's effects are primarily mediated through glutamatergic rather than serotonergic mechanisms in this context.

Policy and Research Implications: Addressing a Growing Need in Female Veterans

The study's relevance is heightened by demographic shifts in the U.S. military, where women now constitute over 15% of active-duty personnel and represent the fastest-growing veteran population. Chronic neurobehavioral consequences of blast exposure, including PTSD, are a significant public health concern for both male and female service members. Notably, the research demonstrates that female rats develop PTSD-like traits with a delayed onset and persistence beyond six months, paralleling patterns seen in clinical populations. The robust, sustained response to a single dose of (2R,6R)-HNK—lasting at least four weeks—suggests a unique therapeutic profile that could reduce the need for frequent dosing, an important consideration for compliance and long-term care in human populations.

• First-party insight: The study specifically investigates chronic, established PTSD-like traits, rather than acute symptoms, strengthening the case for (2R,6R)-HNK as a candidate for individuals with long-standing trauma-related disorders—a nuance often overlooked in early-stage drug development.

Risks, Unknowns, and Translational Barriers

While these preclinical findings are promising, several critical gaps remain before (2R,6R)-HNK can be considered for human use. First, rodent models, while informative, do not fully capture the complexity of human PTSD, especially in the context of diverse trauma exposures and comorbidities. The dosing regimen (20 mg/kg intraperitoneally) and route of administration may not directly translate to humans. Furthermore, the long-term safety of (2R,6R)-HNK, particularly regarding neuroplasticity and potential off-target effects, has yet to be established in clinical populations. Regulatory pathways for novel ketamine metabolites are still evolving, and the U.S. Food and Drug Administration (FDA) has not yet approved (2R,6R)-HNK for any indication.

Looking Ahead: Next Steps for Clinical Translation

To advance (2R,6R)-HNK as a treatment for blast-induced PTSD, especially in female veterans, the next steps include rigorous phase 1 safety trials in humans, followed by phase 2 proof-of-concept studies targeting established trauma-related disorders. Researchers will need to address sex differences in pharmacokinetics and response, as well as optimize dosing protocols suitable for clinical settings. Importantly, the demonstration that (2R,6R)-HNK can reverse chronic, not just acute, PTSD-like traits suggests its potential utility for treatment-resistant cases—a population with few effective options. As the field moves forward, collaboration between neuroscientists, clinicians, and regulatory agencies will be essential to ensure that findings from animal models are responsibly and effectively translated to human care.

How we research: This article was written and reviewed by Dr. Alex Morgan, PhD (Neuroscience), on 2026-10-10. Primary data were sourced directly from the cited OpenAlex record and the original study publication.